Skip to main content

Artemether / lumefantrine Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 15, 2023.

Applies to artemether / lumefantrine: oral tablet.

Serious side effects

Along with its needed effects, artemether / lumefantrine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking artemether / lumefantrine:

More common

Less common

Incidence not known

Other side effects

Some side effects of artemether / lumefantrine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to artemether / lumefantrine: oral tablet.

General

The most common side effects were headache, anorexia, dizziness, asthenia, arthralgia, and myalgia during clinical studies. Most side effects were mild, did not lead to discontinuation of this drug, and resolved. The 6-dose regimen was discontinued due to side effects in 0.2% of adult patients.[Ref]

Nervous system

Very common (10% or more): Headache (up to 56%), dizziness (up to 39%)

Common (1% to 10%): Vertigo, paresthesia, clonus

Uncommon (0.1% to 1%): Somnolence, involuntary muscle contractions, hypoesthesia, ataxia

Frequency not reported: Tinnitus, fine motor delay, hyperreflexia, nystagmus, tremor, ototoxicity (including decreased hearing)[Ref]

Metabolic

Very common (10% or more): Anorexia (up to 40%), decreased appetite

Frequency not reported: Hypokalemia[Ref]

Other

Very common (10% or more): Asthenia (up to 38%), pyrexia/fever (up to 25%), chills (up to 23%), fatigue (up to 17%)

Common (1% to 10%): Malaise, rigors, parasitic infestation, viral infection, abscess

Uncommon (0.1% to 1%): Abnormal gait, gait disturbance

Frequency not reported: Ear infection

Postmarketing reports: Face edema, peripheral edema[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (up to 34%), myalgia (up to 32%)

Common (1% to 10%): Back pain[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 26%), vomiting (up to 17%), abdominal pain (up to 17%)

Common (1% to 10%): Diarrhea, dyspepsia

Frequency not reported: Constipation, dysphagia, peptic ulcer, gastroenteritis, helminthic infection, hookworm infection, oral herpes[Ref]

Psychiatric

Very common (10% or more): Sleep disorder (up to 22%)

Common (1% to 10%): Insomnia

Frequency not reported: Agitation, mood swings[Ref]

Cardiovascular

Very common (10% or more): Palpitations (up to 18%)

Common (1% to 10%): QT interval prolongation on ECG

Frequency not reported: QTc prolongation (including asymptomatic)

Postmarketing reports: Hypertension[Ref]

Hematologic

At least 1 case of autoimmune hemolytic anemia has been attributed to lumefantrine.

Cases of delayed hemolytic anemia have been reported after treatment with this drug, primarily when used for the treatment of severe malaria in patients initially treated with IV/parenteral artesunate.[Ref]

Common (1% to 10%): Splenomegaly, anemia, malaria

Frequency not reported: Eosinophilia, abnormal lymphocyte morphology, decreased hematocrit, decreased platelet count, increased platelet count, decreased WBC count, increased WBC count, hemolytic anemia, Plasmodium falciparum infection, autoimmune hemolytic anemia

Postmarketing reports: Delayed hemolytic anemia, thrombocytopenia[Ref]

Hepatic

Common (1% to 10%): Hepatomegaly, increased liver function tests

Frequency not reported: Increased ALT, increased AST, hepatitis

Postmarketing reports: Jaundice[Ref]

During a study, jaundice was observed in 3 patients after treatment with this drug; however, each patient had elevated serum bilirubin at baseline. Resolution occurred on follow-up.[Ref]

Respiratory

Common (1% to 10%): Cough/coughing, nasopharyngitis, pharyngitis

Frequency not reported: Asthma, pharyngolaryngeal pain, bronchitis, influenza, lower respiratory tract infection, pneumonia, respiratory tract infection, upper respiratory tract infection, rhinitis[Ref]

Dermatologic

Common (1% to 10%): Pruritus, rash

Uncommon (0.1% to 1%): Urticaria

Frequency not reported: Acrodermatitis, impetigo, subcutaneous abscess

Postmarketing reports: Serious skin reactions (bullous eruption), urticaria, angioedema, erythematous rash[Ref]

Hypersensitivity

Postmarketing reports: Hypersensitivity reactions (including urticaria, angioedema), anaphylaxis[Ref]

Genitourinary

Frequency not reported: Hematuria, proteinuria, urinary tract infection

Postmarketing reports: Chromaturia, hemoglobinuria[Ref]

Ocular

Frequency not reported: Conjunctivitis[Ref]

References

1. Product Information. Coartem (artemether-lumefantrine). Novartis Pharmaceuticals. 2009.

2. Lefevre G, Looareesuwan S, Treeprasertsuk S, et al. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg. 2001;64(5-6):247-56.

3. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E. An integrated assessment of the clinical safety of artemether-lumefantrine: a new oral fixed-dose combination antimalarial drug. Trans R Soc Trop Med Hyg. 2000;94:419-24.

4. Artemether-lumefantrine (Coartem) for treatment of malaria. Med Lett Drugs Ther. 2009;51:75-6.

5. Cerner Multum, Inc. UK Summary of Product Characteristics.

6. Cerner Multum, Inc. Australian Product Information.

7. Gurkov R, Eshetu T, Miranda IB, et al. Ototoxicity of artemether / lumefantrine in the treatment of falciparum malaria: a randomized trial. Malar J. 2008;7:179.

8. Toovey S. Effects of weight, age, and time on artemether-lumefantrine associated ototoxicity and evidence of irreversibility. Travel Med Infect Dis. 2006;4:71-6.

9. McCall MB, Beynon AJ, Mylanus EA, van der Ven AJ, Sauerwein RW. No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria. Trans R Soc Trop Med Hyg. 2006;100:1098-104.

10. Toovey S. A case-control auditory evaluation of patients treated with artemether-lumefantrine. Am J Trop Med Hyg. 2006;74:939-40; author reply 940.

11. Stover KR, King ST, Robinson J. Artemether-lumefantrine: an option for malaria. Ann Pharmacother. 2012;46:567-77.

12. McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5:e253.

13. Merat S, Lambert E, Vincenti-Rouquette I, Gidenne S, Rousseau JM, Brinquin L. Case report: combination artemether-lumefantrine and haemolytic anaemia following a malarial attack. Trans R Soc Trop Med Hyg. 2003;97:433-4.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.